Industry User Meetings

Industry User Meetings are open to all attendees. Registration links (if applicable) will be added to this page in the coming weeks. Links to the actual event will be added to this page and to the Networking Room in the meeting platform prior to the start of the event. Please visit the companies in the Virtual Exhibit Hall for further information on these exciting events.  

Saturday, June 12

9:15–10:15 am EDT

A Case-Based Discussion of Detectnet™ (copper Cu 64 dotatate injection) 

  • Andreas Kjaer, MD, PhD (University of Copenhagen, Nuclear Medicine Specialist)

The presentation will focus on clinical data, including results from head-to-head European studies and the US pivotal Phase III trial. The discussion will conclude with several in-depth reviews of recent patient cases with Detectnet and an opportunity for Q&A.

Link to Attend Event on Saturday, June 12 at 9:15am ET:
Passcode: 365056
Meeting ID: 929 2215 9575

9:15–10:15 am EDT

     Accelerating the Future of Nuclear Medicine: Advances in Radioisotope and
   Therapeutic Technologies 
Register for this User Meeting

Join us, industry leaders and customers to discuss NorthStar’s pioneering USA-Made Mo-99, advancements in first-of kind electron accelerators, and plans for strategic collaborations to provide game-changing therapeutics.

Sunday, June 13

7:45-9:45 pm EDT

The Journey to Approval of a Commercially Available 18F-PSMA PET/CT Imaging Agent for Prostate Cancer 
Register for this User Meeting


  • Mary Anne Heino, CEO, Lantheus Medical Imaging
  • Barry A. Siegle, MD, Professor of Radiology and Medicine, Washington University School of Medicine
  • Martin G. Pomper, MD, PhD, Henry N. Wagner, Jr., M.D., Professor, Director, Division of Nuclear Medicine and Molecular Imaging Johns Hopkins Medical School
  • Kenneth J. Pienta, MD, Professor of Urology and Oncology, Johns Hopkins School of Medicine
  • Michael J. Morris, MD, Member and Attending Section Head, Prostate Cancer GU Oncology Service, Memorial Sloan Kettering Cancer Center, Weill Cornell Medicine, Professor of Medicine
  • Andrei Iagaru, MD, Professor of Radiology - Nuclear Medicine, Stanford University

In this session the panel will discuss the discovery and development journey, the research studies, and the clinical implications of an 18F PSMA-targeted prostate cancer imaging isotope. This session will include Q & A. You will learn about:

  • The discovery of an 18F PSMA-targeted isotope at Johns Hopkins University School of Medicine
  • The clinical utility and patient management implications of an 18F PSMA-targeted imaging from the OSPREY and CONDOR pivotal studies
  • Insights into the research access program

7:45-8:45 pm EDT

360º CZT Transformative Innovation
Addressing the challenges of 2D Nuclear Medicine
VERITON-CT Digital SPECT/CT: 3D Imaging and Beyond

Register for this User Meeting

Clinical Presenters:

  • Brigham and Women's Hospital; Boston, MA, USA
  • University Hospital of Toulouse-Purpan; Toulouse, France
  • CHRU Nancy; Nancy, France
  •  Royal United Hospital; Bath, UK


  • Cardiology: Cardiac Amyloidosis Quantitative SECT/CT
  • Neurology: Clinical advantages gained with 360º CZT
  • Total Body Imaging: How 360º CZT enables the transition to diagnostics and more
  • Clinical Case Review: Clinical improvements gained imaging with 360º CZT

Monday, June 14

8:45–9:45 am EDT

      MI in the Age of Personalized Medicine
Register for this User Meeting

8:45–9:45 am EDT

    Cardiac PET Workshop and Roundtable
Register for this User Meeting

Roundtable Moderator:

  • Joe Oliverio, Vice President Clinical Affairs at IONETIX


  • Nils Johnson, MD, MS - Associate Professor, Cardiovascular Medicine, McGovern Medical School, The University of Texas Health Science Center of Houston
  • Robert Bober, MD - Director of Molecular Imaging and Nuclear Cardiology, Ochsner Health
  • Jennifer Renaud, MS - Research Scientist at INVIA Medical Imaging Solutions

In this interactive meeting a general clinical overview of Cardiac PET will be covered.  Additional topics of presentation and discussion will include: Starting a Cardiac PET program, Protocols and patient management, and Image optimization and interpretation.

8:45–9:45 am EDT

 Practical Applications of USP <825>
Register for this User Meeting


  • Lisa Koss, RPh, BCNP
  • Jeanine Halverson, RPh 

US Pharmacopeia (USP) published Chapter 825 and made the guidelines final as of Dec, 31, 2020. This presentation will discuss the history, components and risk levels of USP <825>.  The USP Chapter <825> guidelines for commercial nuclear pharmacies will be presented with practical application approach and details of the changes affecting nuclear medicine departments will be discussed. You will learn how to apply USP <825> standards to your daily radiopharmacy practice. A Q & A panel discussion will follow the presentation.


  • Discuss USP Chapter <825> and history
  • Components and risk levels of USP <825>
  • USP Chapter <825> Requirements for commercial nuclear pharmacies
  • Changes affecting nuclear medicine departments 
  • Applying USP <825> standards to your daily practice

This activity is worth 1.00 CEHs (Continuing Education Hours).

8:45–9:45 am EDT

   MIM Software SNMMI 2021 User Meeting
Register for this User Meeting


  • James Patrick Buteau, MD Nuclear Medicine, Department of Medical Imaging Hôpital Cité de la Santé de Laval, Peter MacCallum Cancer Centre

Nuclear Medicine is evolving, and new opportunities are on the horizon. How are you planning to adapt?
Join MIM Software’s user meeting during the 2021 SNMMI Virtual Annual Meeting to discover the latest advancements in the field.
Our panel of speakers will discuss radiopharmaceutical therapy developments, PET quantitation and its impact in the clinic today and in the future, new PET tracer support, and more.

8:45–9:45 am EDT

    PMOD Virtual User Meeting - SNMMI '21
Register for this User Meeting


  • Prof. Roger Schibli, Head of the Centre for Radiopharmaceutical Sciences, ETH Zurich
  • Dr. Paolo Zanotti-Fregonara, National Institute of Mental Health
  • Mette Lauritzen, PhD, Product Marketing Manager, Nuclear Molecular Imaging
  • Geoff Warnock, Senior Applications Scientist

We look forward to welcoming many of our users to our 2021 PMOD User Meeting. The theme of our PMOD User Meeting will be “Tips & tricks for tracer evaluation and longitudinal studies.” Our two keynote speakers, Prof. Roger Schibli, Head of the Centre for Radiopharmaceutical Sciences, ETH Zurich/Paul Scherrer Institute/University of Zurich, and Dr. Paolo Zanotti-Fregonara, National Institute of Mental Health, will use their experience in development of novel radionuclides for theranostics and fully quantitative PET in tracer evaluation to demonstrate important topics. Following the educational session we will hold a round-table discussion with Prof. Schibli, Dr. Zanotti-Fregonara and our moderators. The theme will be “The needs of the image analysis community in the next two years." We hope that you will join in the discussion!

7:45–8:45 pm EDT

The uMI User Experience
Register for this User Meeting

The discussion of the real-world implementation of the ultra-resolution digital PET/CT from clinical to business perspective.

Tuesday, June 15

8:45–9:45 am EDT

Ultimate tools for research in molecular imaging:
introduction of the AnyScan TRIO SPECT/CT
                                 Register for this User Meeting

  • Dr. Elizabeth Tucker, Assistant Professor of Pediatric Critical Care Medicine, Johns Hopkins University School of Medicine
  • Svend Hvidsten MSc, Department of Nuclear MedicineOdense University Hospital

Presentations will provide an overview of the research done to date using the nanoScan® preclinical molecular imaging platform focusing on new features and developments. We introduce the AnyScan® TRIO SPECT/CT*. This investigational device is the only triple-detector SPECT/CT that is designed for high-end clinical and research applications with both parallel hole and multi-pinhole collimation. Finally, our users will report on their experience using both preclinical (nanoScan®) and clinical (AnyScan® TRIO) research systems.

*The AnyScan® S is currently cleared by FDA under 510(k) K 131625. The other products, such as the AnyScan® TRIO line of products are not currently available for sale in the United States.

8:45–9:45 am EDT

     Latest Developments in Molecular Imaging
Register for this User Meeting


  • Prof. Dr. Freek Beekman, CEO and Founder MILabs, The Netherlands
    Title: 15 Year MILabs including latest product innovations
  • Prof. Dr. Stephen L. Archer MD, Queen’s University, Canada
    Title: SARS-CoV-2 attacks mitochondria in the cardiopulmonary system: an exacerbating mechanism in COVID-19 pneumonia 
  • Dr. Julie Nonnekens, ErasmusMC, The Netherlands
    Title: Radiobiology and molecular imaging of targeted radionuclide therapy